OSE Immunotherapeutics SA ORPOF
Set alert
4.43 USD 0.00 0.00%
At close · Oct 29
Day range unavailable
4.43 52-week range 11.60
- YTD
- -61.81%
- 1 year
- -61.81%
- Open
- —
- Prev close
- 4.43
- Mkt cap
- 109.52M
- Vol
- 0
- Avg vol
- 0
- EPS
- -1.91
- P/E
- 0.00
More statistics
- Low
- —
- High
- —
News
- OSE Immunotherapeutics SA (ORPOF) Lusvertikimab Mechanism and Clinical Progress in Ulcerative Colitis and Chronic Pouchitis Transcript
- OSE Immunotherapeutics SA (ORPOF) Discussion of Tedopi Immunotherapy Pipeline and Clinical Progress Across Oncology Indications Transcript
- OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
- OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
- OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
- OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
- OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
- OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
- OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
- OSE Immunotherapeutics Evolves its Leadership Team
Your note
Sign in to keep a note on ORPOF — it syncs with the Stock Master app.